By Kathryn Hardison
Shares of Imara Inc. fell 11% to $3.39 Monday after the company's all-stock deal to merge with oncology company Enliven Therapeutics Inc. sent shares higher Friday.
The combined company, which will be called Enliven Therapeutics Inc., will focus on Enliven's pipeline of precision oncology product candidates, the companies said late Thursday. The combined company will trade on the Nasdaq Global Select Market under the ticker symbol ELVN.
Shareholders of both companies still need to approve the merger, though Imara and Enliven said they expect the deal to close in the first quarter of next year.
Shares on Friday reached an intraday high of $3.82 before closing at $3.79, according to FactSet.
Shares Monday traded 51% higher for the year.
Write to Kathryn Hardison at kathryn.hardison@wsj.com
(END) Dow Jones Newswires
October 17, 2022 12:11 ET (16:11 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。